Sweet's syndrome in a granulocytopenic patient with acute myeloid leukemia on FLT3 inhibitor

• Autori principali: Anish Paudel (Autore), Rashmi Dhital (Autore), Gabriel Areoye (Autore), Sijan Basnet (Autore), Niranjan Tachamo (Autore)
• Natura: Libro
• Pubblicazione: Greater Baltimore Medical Center, 2020-05-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Introduction Gilteritinib is a FLT3 kinase inhibitor approved for FLT3-mutated acute myeloid leukemia (AML). We present a case of febrile neutropenia and neutrophilic dermatosis consistent with Sweet's syndrome (SS). Case history A 55-year-old woman presented with fever and skin lesions after 4...